Ascendis Pharma aims for USD 400m from share issue

A week after Ascendis Pharma received approval for its once-weekly growth hormone treatment, the biotech company has started to look for capital.
Photo: Kevin Grønnemann/MedWatch
Photo: Kevin Grønnemann/MedWatch
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT

Ascendis Pharma wants to bulk up its economic muscles and has therefore started an equity issuance the company hopes can bring in USD 400m (DKK 2.5bn) to the firm.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading